资料显示，北京昭衍新药研究中心股份有限公司(股票代码:603127.SH/6127.HK),成立于1995年,是专业化 的药物研发服务外包企业(CRO),总部位于北京,在北京、苏州、重庆、广州、无锡、梧州、南宁、云 南、上海、美国加州及波士顿设有子公司,昭衍新药建立有符合国际规范的质量管理体系(CNAS/ILAC- MRA认证),具备中国NMPA、美国FDA、日本PMDA、韩国MFDS及经合组织OECD的GLP资质以及国际 AAALAC(动物福利)认证资质,评价资料满足全球药品注册要求。 *注：AH股是指同时在A股和港股上市的公司，溢价（A/H）越大，说明H股相比A股越便宜。 本文源自：金融界 作者：行情君 8月14日，上证指数跌0.46%，收报3666.44点，恒生指数跌0.37%，收报25519.32点。 XD昭衍新AH溢价达43.47%，位居AH股溢价率第79位。当日收盘，XD昭衍新A股报32.21元，跌幅 5.74%，H股报24.56港元，下跌1.52%。 ...

Company Overview - Beijing Zhaoyan New Drug Research Center Co., Ltd. (stock code: 603127.SH/6127.HK) is a specialized drug research and development service outsourcing company (CRO) established in 1995, headquartered in Beijing [4] - The company has subsidiaries in multiple locations including Suzhou, Chongqing, Guangzhou, Wuxi, Wuzhou, Nanning, Yunnan, Shanghai, California, and Boston, and has established a quality management system compliant with international standards [4] - Zhaoyan New Drug provides a one-stop service for non-clinical pharmacology and toxicology research, clinical trials, and drug safety monitoring, as well as evaluations for veterinary drugs, pesticides, and medical devices [4] Financial Performance - As of March 31, 2025, Zhaoyan New Drug reported total operating revenue of 287 million yuan, a year-on-year decrease of 11.54%, while net profit attributable to shareholders was 41.12 million yuan, a year-on-year increase of 115.11% [2] - The company's gross profit margin stands at 28.61%, and its asset-liability ratio is 13.96% [2] Stock Performance - Over the past month, Zhaoyan New Drug has seen a cumulative increase of 30.66%, and a year-to-date increase of 35.83%, outperforming the Hang Seng Index by 17.51% [2] - The stock closed at 14.18 HKD per share on May 30, with a trading volume of 36.01 million shares and a turnover of 507 million HKD, reflecting a volatility of 22.52% [1] Industry Valuation - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 5.64 times, with a median of 5.97 times, while Zhaoyan New Drug's P/E ratio is 22.4 times, ranking 52nd in the industry [3] - Comparatively, other companies in the industry have significantly lower P/E ratios, such as Qingdao Haier Biomedical (0.68 times) and King’s Ray Biotechnology (1.22 times) [3] Upcoming Events - The company plans to distribute a dividend of 0.03 RMB per share (approximately 0.032512 HKD) for the fiscal year ending in 2024, with the ex-dividend date set for June 26, 2025, and the payment date on August 31, 2025 [5]